| TGF-beta-RII binding proteins |
2023-2-13 |
2023-3-09 |
|
| Mixed binding domains |
2022-12-12 |
2023-2-02 |
|
| Methods and means for the production of ig-like molecules |
2022-11-20 |
2023-1-01 |
|
| Treatment of cancers with an antibody that binds lgr5 and egfr |
2022-10-19 |
2022-12-01 |
|
| Treatment of immune checkpoint inhibitor-treated cancers with high egfr … |
2022-10-06 |
2023-4-13 |
|
| Means and method for modulating immune cell engaging effects |
2022-6-28 |
2022-8-01 |
|
| New nrg1 fusions, fusion junctions and methods for detecting them |
2022-6-01 |
2022-12-08 |
|
| Liquid biopsy assays for detecting nrg1 fusion polynucleotides |
2022-6-01 |
2023-1-12 |
|
| Novel pd-1 binding domains |
2022-3-31 |
2022-10-06 |
|
| Novel multispecific antibodies |
2022-3-30 |
2022-10-06 |
|
| Multispecific binding moieties comprising novel pd-1 binding domains |
2022-3-30 |
2022-10-06 |
|
| Antibody that binds erbb-2 and erbb-3 |
2022-2-18 |
2022-11-03 |
|
| Modified human variable domains |
2022-2-06 |
2022-4-01 |
|
| Treatment of cancer with a combination of an antibody that binds lgr5 and egfr … |
2022-1-30 |
2022-3-01 |
|
| Antibody composition |
2021-12-16 |
2022-6-23 |
|
| Treatment of cancers with an antibody that binds lgr5 and egfr |
2021-12-15 |
2022-6-23 |
|
| Multispecific antibodies for the treatment of cancer |
2021-12-03 |
2022-6-23 |
|
| Variant domains for multimerizing proteins and separation thereof |
2021-11-08 |
2022-1-01 |
|
| Means and methods for treating subjects with erbb3 mutation positive cancer |
2021-11-03 |
2022-5-12 |
|
| Method for detecting expression or clustering of cell surface moieties |
2021-9-28 |
2022-3-31 |
|
| Method for detecting expression or clustering of cell surface moieties |
2021-9-28 |
2022-3-31 |
|
| Cd3 binding molecules |
2021-8-31 |
2021-10-31 |
|
| Combinations of binding moieties that bind egfr, her2 and her3 |
2021-8-10 |
2021-9-30 |
|
| Producing compositions comprising two or more antibodies |
2021-8-10 |
2021-9-30 |
|
| Truncated multivalent multimers |
2021-6-03 |
2021-7-29 |
|
| Antibodies that bind EGFR and cMET |
2021-5-06 |
2021-6-03 |
|
| Binding molecules that modulate a biological activity expressed by a cell |
2021-4-06 |
2021-4-29 |
|
| Binding molecules that inhibit cancer growth |
2021-3-24 |
2021-7-09 |
|
| Means and methods for treating subjects with HER2 and HER3 positive cancer |
2020-10-23 |
2022-5-12 |
|
| Antibodies that bind egfr and erbb3 |
2020-10-21 |
2021-5-27 |
|
| Multivalent antibody |
2020-9-29 |
2020-11-30 |
|
| Generation of binding molecules |
2020-9-28 |
2020-10-29 |
|
| Bispecific antibody |
2020-7-29 |
2022-9-08 |
|
| Methods and means for the production of ig-like molecules |
2020-7-21 |
2021-3-11 |
|
| Antibody producing non-human animals |
2020-6-19 |
2020-10-08 |
|
| Antibody producing non-human mammals |
2020-5-07 |
2020-5-28 |
|
| Bispecific antibody |
2020-4-03 |
2022-6-16 |
|
| CD3 BINDING MOLECULES |
2020-3-27 |
2021-10-20 |
|
| PRODUCTION OF COMPOSITIONS INCLUDING TWO OR MORE ANTIBODIES |
2020-2-14 |
2021-9-15 |
|
| PRODUCTION OF COMPOSITIONS COMPRISING TWO OR MORE ANTIBODIES |
2020-2-13 |
2021-10-26 |
|
| COMBINATIONS OF BINDING PORTIONS THAT BIND TO EGFR, HER2 AND HER3 |
2020-2-13 |
2021-10-26 |
|
| Bispecific anti pd1-anti tim3 antibodies |
2020-1-06 |
2020-10-12 |
|
| Binding molecules that modulate a biological activity expressed by a cell |
2020-1-06 |
2020-10-12 |
|
| Antibodies that modulate a biological activity expressed by a cell |
2020-1-06 |
2020-10-12 |
|
| CLEC12AXCD3 BISPECIFIC ANTIBODIES AND METHODS OF TREATING A DISEASE |
2019-12-20 |
2021-10-27 |
|
| Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for … |
2019-11-18 |
2020-12-07 |
|
| Recombinant production of mixtures of antibodies |
2019-10-16 |
2019-11-07 |
|
| Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells … |
2019-9-27 |
2020-7-13 |
|
| Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites … |
2019-9-27 |
2020-7-13 |
|
| Bispecific igg antibodies as t cell engagers |
2019-4-19 |
2019-11-21 |
|
| Bispecific antibody |
2019-2-08 |
2021-7-15 |
|
| Human CD3 Binding Antibody |
2019-1-11 |
2019-7-11 |
|
| Combination therapy with bispecific antibody and I L-15 |
2018-11-30 |
2020-7-17 |
|
| Binding molecules that inhibit cancer growth |
2018-4-23 |
2018-6-28 |
|
| Antibodies for the treatment of erbb-2/erbb-3 positive tumors |
2018-4-03 |
2020-2-05 |
|
| Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites … |
2018-4-03 |
2021-7-08 |
|
| Antibody producing non-human animals |
2018-1-12 |
2018-5-24 |
|
| Recombinant production of mixtures of antibodies |
2017-12-27 |
2018-4-26 |
|
| Binding molecules that inhibit cancer growth |
2016-10-21 |
2021-4-15 |
|
| Recombinant production of mixtures of antibodies |
2016-5-18 |
2019-12-17 |
2019-12-17 |
| Antibody that binds erbb-2 and erbb-3 |
2015-2-27 |
2020-12-04 |
|
| Bispecific igg antibodies as t cell engagers |
2013-9-27 |
2023-4-11 |
2023-4-11 |
| Traitement de cancers traités par un inhibiteur de point de contrôle … |
2022-10-06 |
2023-4-13 |
|
| Produção de composições que compreendem dois ou mais anticorpos |
2020-2-13 |
2021-10-26 |
|
| Combinações de porções de ligação que se ligam ao egfr, her2 e her3 |
2020-2-13 |
2021-10-26 |
|
| Anticorps bispecifiques de type igg comme activateurs de lymphocytes t |
2013-9-27 |
2023-4-11 |
2023-4-11 |